{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:57:31Z","timestamp":1784591851309,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.4158\/ep13172.or","type":"journal-article","created":{"date-parts":[[2013,10,14]],"date-time":"2013-10-14T21:08:02Z","timestamp":1381784882000},"page":"213-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Complete Blood Counts are Frequently Abnormal 1 Year after Dosimetry-Guided Radioactive Iodine Therapy for Metastatic Thyroid Cancer"],"prefix":"10.1016","volume":"20","author":[{"given":"Rosalia P.","family":"Padovani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Michael","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinder","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve M.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Boucai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP13172.OR_bb0005","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/thy.2009.0110","article-title":"Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer","volume":"19","author":"American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer","year":"2009","journal-title":"Thyroid"},{"key":"10.4158\/EP13172.OR_bb0010","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1089\/thy.2008.0430","article-title":"Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation","volume":"19","author":"Molinaro","year":"2009","journal-title":"Thyroid."},{"key":"10.4158\/EP13172.OR_bb0015","first-page":"1551","article-title":"Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma","volume":"39","author":"Alexander","year":"1998","journal-title":"J Nucl Med"},{"key":"10.4158\/EP13172.OR_bb0020","first-page":"1549","article-title":"Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer","volume":"45","author":"de Keizer","year":"2004","journal-title":"J Nucl Med."},{"key":"10.4158\/EP13172.OR_bb0025","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1210\/jc.2002-020210","article-title":"Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma","volume":"87","author":"Kloos","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP13172.OR_bb0030","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s002590050535","article-title":"Testicular function after radioiodine therapy for thyroid carcinoma","volume":"27","author":"Wichers","year":"2000","journal-title":"Eur J Nucl Med."},{"key":"10.4158\/EP13172.OR_bb0035","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/pmj.78.916.92","article-title":"Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer","volume":"78","author":"Vini","year":"2002","journal-title":"Postgrad Med J."},{"key":"10.4158\/EP13172.OR_bb0040","first-page":"85","article-title":"Hematologic changes observed following I-131 therapy for thyroid carcinoma","volume":"4","author":"Haynie","year":"1963","journal-title":"J Nucl Med."},{"key":"10.4158\/EP13172.OR_bb0045","first-page":"475","article-title":"Long-term hematologic changes caused by radioiodine treatment of thyroid cancer. II. Bone marrow changes including leukemia [in German]","volume":"163","author":"G\u00fcnter","year":"1987","journal-title":"Strahlenther Onkol."},{"key":"10.4158\/EP13172.OR_bb0050","first-page":"171","article-title":"The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer","volume":"87","author":"Benua","year":"1962","journal-title":"Am J Roentgenol Radium Ther Nucl Med."},{"key":"10.4158\/EP13172.OR_bb0055","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/sj.bjc.6601319","article-title":"Second primary malignancies in thyroid cancer patients","volume":"89","author":"Rubino","year":"2003","journal-title":"Br J Cancer."},{"key":"10.4158\/EP13172.OR_bb0060","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1210\/jc.2007-1154","article-title":"The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer","volume":"93","author":"Brown","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP13172.OR_bb0065","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0360-3016(00)01587-X","article-title":"Effect of fractionated regional external beam radiotherapy on peripheral blood cell count","volume":"50","author":"Zachariah","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"Suppl 1","key":"10.4158\/EP13172.OR_bb0070","first-page":"28S","article-title":"The evolving role of (131)I for the treatment of differentiated thyroid carcinoma","volume":"46","author":"Robbins","year":"2005","journal-title":"J Nucl Med."},{"key":"10.4158\/EP13172.OR_bb0075","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1210\/jc.2011-0305","article-title":"Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH","volume":"96","author":"Tala","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP13172.OR_bb0080","first-page":"1482","article-title":"A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation","volume":"43","author":"Robbins","year":"2002","journal-title":"J Nucl Med."},{"key":"10.4158\/EP13172.OR_bb0085","first-page":"1587","article-title":"Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer","volume":"47","author":"Tuttle","year":"2006","journal-title":"J Nucl Med."},{"key":"10.4158\/EP13172.OR_bb0090","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1089\/thy.2006.16.1019","article-title":"The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer","volume":"16","author":"Kulkarni","year":"2006","journal-title":"Thyroid."},{"key":"10.4158\/EP13172.OR_bb0095","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.2967\/jnumed.108.050591","article-title":"Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity","volume":"49","author":"Ros\u00e1rio","year":"2008","journal-title":"J Nucl Med."},{"key":"10.4158\/EP13172.OR_bb0100","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1089\/thy.2011.0235","article-title":"Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin","volume":"22","author":"Klubo-Gwiezdzinska","year":"2012","journal-title":"Thyroid."},{"key":"10.4158\/EP13172.OR_bb0105","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/bjc.1973.142","article-title":"Induction of leukemia by 131-I treatment of thyroid carcinoma","volume":"28","author":"Brincker","year":"1973","journal-title":"Br J Cancer."},{"key":"10.4158\/EP13172.OR_bb0110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1259\/0007-1285-59-697-45","article-title":"The long-term hazards of the treatment of thyroid cancer with radioiodine","volume":"59","author":"Edmonds","year":"1986","journal-title":"Br J Radiol."},{"key":"10.4158\/EP13172.OR_bb0115","first-page":"337","article-title":"Subsequent malignancies in patients treated with 131-iodine for thyroid cancer","volume":"168","author":"Glanzmann","year":"1992","journal-title":"Strahlenther Onkol."},{"key":"10.4158\/EP13172.OR_bb0120","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/bjc.1997.130","article-title":"Leukaemias and cancers following iodine-131 administration for thyroid cancer","volume":"75","author":"de Vathaire","year":"1997","journal-title":"Br J Cancer."},{"key":"10.4158\/EP13172.OR_bb0125","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1210\/jc.2005-2009","article-title":"Second primary cancers in thyroid cancer patients: a multinational record linkage study","volume":"91","author":"Sandeep","year":"2006","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20432458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20432458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/R2014P277X67T24M.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:56:13Z","timestamp":1761515773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20432458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1530891X20432458"],"URL":"https:\/\/doi.org\/10.4158\/ep13172.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complete Blood Counts are Frequently Abnormal 1 Year after Dosimetry-Guided Radioactive Iodine Therapy for Metastatic Thyroid Cancer","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP13172.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}